Literature DB >> 27951533

Correlations of Plasma Desphosphorylated Uncarboxylated Matrix Gla Protein with Vascular Calcification and Vascular Stiffness in Chronic Kidney Disease.

Sipanan Thamratnopkoon1, Paweena Susantitaphong, Monravee Tumkosit, Pisut Katavetin, Khajohn Tiranathanagul, Kearkiat Praditpornsilpa, Somchai Eiam-Ong.   

Abstract

BACKGROUND: Matrix Gla protein (MGP) is a potent inhibitor of vascular calcification and needs vitamin K-dependent carboxylation for its activity. High levels of desphosphorylated uncarboxylated MGP (dp-ucMGP) were significantly associated with vitamin K deficiency and vascular calcification. This study was conducted to explore the correlations of plasma dp-ucMGP with vascular calcification and vascular stiffness in chronic kidney disease (CKD) patients.
METHODS: This cross-sectional study enrolled 83 CKD stages 3-5 patients. Vascular calcification score was determined by calcific lesions in the abdominal aorta (AAC) shown by lateral lumbar film; vascular stiffness was assessed by cardio-ankle vascular index (CAVI) and pulse wave velocity, while plasma dp-ucMGP levels were measured using ELISA method. Multivariate regression analyses were used to select factors that were independently associated with vascular calcification and vascular stiffness.
RESULTS: The mean age was 62.9 ± 13.9 years. CKD stages 3, 4, and 5 constituted 51.8, 13.3, and 34.9%, respectively. The median of plasma dp-ucMGP levels in CKD stages 3, 4, and 5 were 586 (452-888), 870 (594-1,591), and 1,050 (518-1,298) pmol/L, respectively. The prevalence of vascular calcification (AAC score ≥1) was 63.4% and that of vascular stiffness (CAVI ≥9) was 46.3%. Vascular calcification was correlated with vascular stiffness (r2 = 0.50, p < 0.001). Multivariate logistic regression analysis models to predict vascular calcification showed that age and plasma dp-ucMGP levels were significantly correlated with vascular calcification (OR 1.21; 95% CI 1.09-1.33; p < 0.001 and OR 1.002; 95% CI 1.001-1.004; p = 0.004, respectively). In contrast, there was no association between plasma dp-ucMGP levels and vascular stiffness.
CONCLUSIONS: Plasma dp-ucMGP levels increase according to the severity of CKD. Plasma dp-ucMGP was positively associated with vascular calcification and might be utilized as an early marker for vascular calcification in CKD patients.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27951533     DOI: 10.1159/000453368

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  21 in total

1.  Reversible cerebral vasoconstriction syndrome and antivitamin K anticoagulation: challenges of an unusual association.

Authors:  Amina Nasri; Malek Mansour; Amel Kacem; Jamel Zaouali; Ridha Mrissa
Journal:  Neurol Sci       Date:  2017-05-13       Impact factor: 3.307

Review 2.  Vitamin K effects in human health: new insights beyond bone and cardiovascular health.

Authors:  Maria Fusaro; Maurizio Gallieni; Camillo Porta; Thomas L Nickolas; Pascale Khairallah
Journal:  J Nephrol       Date:  2019-12-19       Impact factor: 3.902

3.  Circulating Dephospho-Uncarboxylated Matrix Gla-Protein Is Associated With Kidney Dysfunction and Arterial Stiffness.

Authors:  Houry Puzantian; Scott R Akers; Garrett Oldland; Khuzaima Javaid; Rachana Miller; Yueya Ge; Bilal Ansari; Jonathan Lee; Arpita Suri; Zeba Hasmath; Raymond Townsend; Julio A Chirinos
Journal:  Am J Hypertens       Date:  2018-08-03       Impact factor: 2.689

Review 4.  Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease.

Authors:  Nadine Khouzam; Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2017-09-22       Impact factor: 3.714

Review 5.  Phosphate Is a Cardiovascular Toxin.

Authors:  Maren Leifheit-Nestler; Isabel Vogt; Dieter Haffner; Beatrice Richter
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Matrix Gla Protein Levels Are Associated With Arterial Stiffness and Incident Heart Failure With Preserved Ejection Fraction.

Authors:  Rajeev Malhotra; Christopher J Nicholson; Dongyu Wang; Vijeta Bhambhani; Samantha Paniagua; Charles Slocum; Haakon H Sigurslid; Christian L Lino Cardenas; Rebecca Li; Sophie L Boerboom; Yin-Ching Chen; Shih-Jen Hwang; Chen Yao; Fumito Ichinose; Donald B Bloch; Mark E Lindsay; Gregory D Lewis; Jayashri R Aragam; Udo Hoffmann; Gary F Mitchell; Naomi M Hamburg; Ramachandran S Vasan; Emelia J Benjamin; Martin G Larson; Warren M Zapol; Susan Cheng; Jason D Roh; Christopher J O'Donnell; Christopher Nguyen; Daniel Levy; Jennifer E Ho
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-11-23       Impact factor: 8.311

Review 7.  Dysbiosis in Patients with Chronic Kidney Disease: Let Us Talk About Vitamin K.

Authors:  Julie Ann Kemp; Livia Alvarenga; Ludmila F M F Cardozo; Lu Dai; Peter Stenvinkel; Paul G Shiels; Tilman M Hackeng; Leon J Schurgers; Denise Mafra
Journal:  Curr Nutr Rep       Date:  2022-09-23

Review 8.  The Role of Vitamin K Status in Cardiovascular Health: Evidence from Observational and Clinical Studies.

Authors:  A J van Ballegooijen; J W Beulens
Journal:  Curr Nutr Rep       Date:  2017-07-10

Review 9.  Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression.

Authors:  Esmeralda Castillo-Rodriguez; Raul Fernandez-Prado; Raquel Esteras; Maria Vanessa Perez-Gomez; Carolina Gracia-Iguacel; Beatriz Fernandez-Fernandez; Mehmet Kanbay; Alberto Tejedor; Alberto Lazaro; Marta Ruiz-Ortega; Emilio Gonzalez-Parra; Ana B Sanz; Alberto Ortiz; Maria Dolores Sanchez-Niño
Journal:  Toxins (Basel)       Date:  2018-07-19       Impact factor: 4.546

Review 10.  Current Therapy in CKD Patients Can Affect Vitamin K Status.

Authors:  Mario Cozzolino; Giuseppe Cianciolo; Manuel Alfredo Podestà; Paola Ciceri; Andrea Galassi; Lorenzo Gasperoni; Gaetano La Manna
Journal:  Nutrients       Date:  2020-05-30       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.